🎯 Drug Targets

Browse 7 drug targets with druggability analysis, composite scores, and clinical context

Targets

High Druggability

0.51

Avg Score

Target Classes

Druggability Distribution

High: 0Medium: 7Low: 0Unknown: 0

Avg druggability score: 0.534

Clinical Pipeline

Approved: 3Phase III: 0Phase II: 1Phase I: 1Preclinical: 2

Total compounds: 8 · Approved: 5

Filtered by: class=signaling_protein, druggability=Medium — 7 results

C3 Complement C3 Approved

Signaling Protein Medium Druggability

Small molecule inhibitor of complement activation or convertase activity

NLRP3 NACHT, LRR and PYD domains-containing protein 3 Approved

Signaling Protein Medium Druggability

Small molecule inhibitors targeting NLRP3 inflammasome assembly or activation

G3BP1 Ras GTPase-activating protein-binding protein 1 Phase II

Signaling Protein Medium Druggability

G3BP1 inhibitors would prevent stress granule assembly and stabilization by disrupting the interaction between G3BP1 and its binding partners, potentially reducing pathological aggregation of TDP-43 and FUS proteins. This mechanism could alleviate neurodegeneration in conditions characterized by aberrant stress granule formation and RNA metabolism dysfunction.

TNFA Tumor necrosis factor alpha Approved

Signaling Protein Medium Druggability

Monoclonal antibodies or soluble receptors that neutralize TNF-alpha activity

PIEZO1ANDKCNK2 PIEZO1ANDKCNK2

Signaling Protein Medium Druggability

Prioritized from 1 SciDEX hypotheses, including: Mechanosensitive Ion Channel Reprogramming

DGAT1ANDSOAT1 DGAT1ANDSOAT1

Signaling Protein Medium Druggability

Prioritized from 1 SciDEX hypotheses, including: Lipid Droplet Dynamics as Phenotype Switches

MITOCHONDRIALBIOGENESISGENES MITOCHONDRIALBIOGENESISGENES Phase I

Signaling Protein Medium Druggability

Prioritized from 1 SciDEX hypotheses, including: Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits